Advanced Circulatory Systems Inc. released positive results for a clinical trial for its ResQPump and ResQPOD cardiopulmonary resuscitation assistance devices.
The Roseville, Minn.-based CPR device developer and manufacturer said results from the study showed that the devices, when used in tandem, gave cardiac arrest victims a 53 percent better chance of survival than if they received standard CPR.
The trial, funded by the National Institutes of Health and sponsored by ACSI, compared survival rates of 813 cardiac arrest patients given CPR without the devices and 840 others treated with the assistance of the two devices, according to the company. About 5 percent of the 300,000 Americans who experience out-of-hospital cardiac arrest survive, according to University of Minnesota professor Dr. Ralph Frascone, who presented the results of the study on Nov. 14 at American Heart Association Resuscitation Science Symposium in Chicago.
ACSI designed its ResQPOD to regulate airflow through a medical facemask and decreases the amount of unnecessary respiratory gas in a patient. The ResQPump was designed to help rescuers tell how much force they need to use when giving chest compressions and gives them the ability to pull the chest back up, allowing more blood to flow back in to the chest cavity.
The ResQPOD device is already approved for use in the United States. The ResQPump has not yet recevied regulatory approval fom the Food & Drug Administration and is only available outside the U.S.
